Skip to main content


  • Case report
  • Open Access

Postoperative infection caused by Acinetobacter baumannii misdiagnosed as a free-living amoeba species in a humeral head hemiarthroplasty patient: a case report

Contributed equally
Infectious Diseases of Poverty20187:33

  • Received: 24 June 2017
  • Accepted: 19 March 2018
  • Published:



Acinetobacter baumannii is ubiquitous, facultative intracellular, and opportunistic bacterial pathogen. Its unique abilities allow it to survive in a diverse range of environments, including health care settings, leading to nosocomial infections. And its exceptional ability to develop resistance to multiple antibiotics leaves few drug options for treatment. It has been recognized as a leading cause of nosocomial pneumonia and bacteremia over the world.

Case presentation

In this case, a 73-year-old woman presented with a Neer Group VI proximal humeral fracture. Six hours after a successfully performed hemiarthroplasty, she developed continuous fever. Clinical examination revealed that the vitals were regular. Laboratory and radiographic examinations revealed only elevated procalcitonin levels. Blood culture revealed no bacterial or fungal growth. Cooling treatment and empirical broad-spectrum antibiotic therapy showed no apparent effect.


We report a postoperative infection caused by Acinetobacter baumannii. The infectious pathogen was identified via molecular DNA sequencing and was initially misidentified as a free-living amoeba species upon microscopic examinations. The patient was mistreated with antiamebic combination therapy. Her symptoms persisted for over 4 months and were eventually followed by her death.


  • Acinetobacter baumannii
  • Free-living amoebae
  • Hemiarthroplasty
  • Case report

Multilingual abstracts

Please see Additional file 1 for translations of the abstract into the five official working laguages of the United Nations.


During the past few decades, Acinetobacter baumannii has received significant attention from scientific and medical communities [15]. Its unique abilities, such as intrinsically resistance to desiccation, allow it to survive in a diverse range of environments, including health care settings, leading to nosocomial infections and troublesome outbreaks [6]. As a nosocomial pathogen which is most commonly involved in hospital infections, A. baumannii has an exceptional ability to develop resistance to multiple antibiotics, leaving few drug options for treatment [3, 68]. Inappropriate initial antimicrobials were strongly associated with increased mortality for A. baumannii infections [9]. In various parts over the globe, it has been recognized as a leading cause of nosocomial pneumonia and bacteremia [1013].

Clinically, A. baumannii usually affects fragile, immunocompromised patients, especially those who suffer from burns, have trauma, or are in the intensive care units (ICUs) [14]. Those infected are commonly associated with mechanical ventilation, intravenous and urinary catheterization, surgery, invasive procedures, and prolonged broad-spectrum antimicrobials [1520]. Clinical reports suggest that Acinetobacter can cause serious, life-threatening infections [6].

In this case report, we describe a rare case of infection caused by Acinetobacter baumannii misdiagnosed as a free-living amoeba (FLA) species and mistreated with an antiamebic combination therapy with metronidazole, fluconazole, compounded sulfamethoxazole and sulfadiazine (COSMZ), dihydroartemisinin and piperaquine phosphate combined (Duo-Cotecxin), and meropenem in a 73-year-old woman admitted to the Department of Orthopaedic Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Case presentation

A 73-year-old woman presented with severe pain in the left upper extremity following a ground-level fall at her home. Physical examination revealed shoulder deformity and restricted range of motion, crepitus from the fracture fragments and extensive ecchymosis to the elbow on her left shoulder. No neurovascular impairment was found. Plain radiographs and computed tomography (CT) scans showed a Neer Group VI proximal humeral fracture (Fig. 1a-b) [21]. Her medical history was significant for lacunar infarction, hypertension, type 2 diabetes and schizophrenia, which were all controlled with oral medications. She was diagnosed with schizophrenia by the Shanghai Mental Health Center. Medical records showed that the patient had irregular fever along with symptoms of schizophrenia such as impulsive tendencies of self-mutilation and aggressive behaviors over decades. Additionally, the patient had a history of eating raw clams (Tegillarca granosa) and years of working barefoot in paddy fields without wearing protective clothing.
Fig. 1
Fig. 1

Radiograpic findings of the left shoulder and ruptrured blisters in the left leg. a: Plain radiograph showing the patient’s left shoulder at admission. b: CT scans of the same area. c: Plain radiograph of the left shoulder after hemiarthroplasty surgery. d: During the treatment failure stage, the patient developed multiple blisters in the left leg. Defects in the skin developed after the blisters ruptured (arrows)

In this case, the patient stayed in hospital for 134 days. On the basis of the maximum body temperature and laboratory examinations, hospitalization was divided into three stages, namely, fever of unknown origin (FUO) stage (days 1–36), antiamebic treatment (AT) stage (days 37–85), and treatment failure (TF) stage (days 86–134) (Additional files 2 and 3).

Fever of unknown origin stage (FUO, days 1–36)

After surgery contraindications were ruled out, the patient underwent a hemiarthroplasty surgery performed by an experienced orthopedic surgeon on day 9 (Fig. 1c). The operation was successfully performed without any intraoperative complications. Six hours after the surgery, she developed continuous fever (body temperature 40.3 °C) (Fig. 2b). Measures for lowering body temperature were taken immediately. Physical examination showed her vitals were normal. The patient had negative Kernig’s sign and neck stiffness. Motor, sensory and cranial nerve examinations were within normal limits. Laboratory and radiographic examinations revealed no obvious evidence of infection, except for elevated procalcitonin levels (0.38 ng/ml, normal levels 0–0.1 ng/ml). Blood (1,3)-β-D-glucan assays were taken 5 times during this stage, and the results were negative. Blood culture was performed several times and revealed no bacterial or fungal growth. Meropenem, cefoperazone/sulbactam, cefathiamidine, vancomycin, azithromycin, fluconazole, ceftazidime, phosphonomycin and linezolid were used as mono- or combination antibiotic therapy successively. The operated upper limb healed uneventfully. However, cooling treatment and empirical broad-spectrum antibiotic therapy showed no apparent effect.
Fig. 2
Fig. 2

Line chart demonstrate a: Blood white blood cell count, b: Maximum body temperature, c: neutrophil count, and d: Neutrophil percentage during hospitalization. The time periods when antibiotics and antiamebics were used are shown

Antiamebic treatment stage (AT, days 37–85)

To investigate the etiology of continuous fever, blood, urine and cerebrospinal fluid (CSF) samples were sent for parasite detection. Surprisingly, large numbers of FLA-like pathogens were discovered microscopically (Fig. 3a, c; Fig. 4). The patient was initially diagnosed as having FLA infection and treated with antiamebic therapy.
Fig. 3
Fig. 3

Microscopic findings in blood samples before and after treatment. a: Differential interference contrast images of the patient’s blood. The cells were discoid in shape, and the cytoplasmic humps were surrounded with flattened hyaline margins, some of which were fan-shaped. Insets are Giemsa-stained blood film images. b: Box chart showing FLA-like pathogen counts per high power magnification (100 ×) field in blood samples at three different time points. At each time point, 20 blood samples were sent for FLA pathogen counting. c: Light microscopic images of the patient’s blood before (af) and after treatment (gn). After treatment, most forms are oval. g–n: Locomotive cells display short filopodia or conical non-branching pseudopodia arising from apical and/or lateral parts of the cell. g, h: Small cells showing refractive outline with single long (over 10 μm) filopodia. i, j: Large irregular cells with short (3–5 μm) filopodia. Scale bars: 10 μm

Fig. 4
Fig. 4

Microscopic findings in CSF and urine samples before treatment. a: Inverted microscopic images of the patient’s CSF. a–c: Irregularly shaped cells with vacuoles. c: Irregularly shaped cells with finger pseudopodia. d: Cells with transparent circular shells; no structures were observed. e: Black sphere. b: Differential interference contrast light microscopic images of the patient’s urine. f–h, j, l, n: Spherical cells. k: Cells with huge vacuoles. m: Cell with fan-shaped pseudopodia. Some “cells” cluster together. Scale bars: 10 μm

On day 37, after the diagnosis of FLA infection was made, the patient was immediately started on a combination therapy with metronidazole, fluconazole, compounded sulfamethoxazole and sulfadiazine (COSMZ), and meropenem [2226]. Meropenem was used in case that the patient was infected with other pathogens in addition to FLA. On day 52, Duo-Cotecxin (Beijing Holley-Cotec Pharmaceuticals Co., Ltd., China) was added to the antiamebic therapy. Additionally, the medical team attempted to obtain miltefosine, which did not arrive in time. From day 61–85, remission of clinical manifestations of the patient was observed. During this period, her mental status remained stable, no schizophrenia related symptoms appeared, and the body temperature was lower than 38.0 °C most of the time (Fig. 2b). Laboratory results were normal. A decrease in FLA-like pathogen from 5.25 to 1.95 counts under high power field at magnification (× 100) field in blood samples was also observed by microscopy (Fig. 3b).

Treatment failure stage (TF, days 86–134)

Although a remission of clinical manifestations of the patient was observed for approximately 25 days (days 61 to 85), the patient’s condition deteriorated from day 86. Her body temperature was higher than 38.0 °C most of the time (Fig. 2b), and the FLA-like pathogen count in the blood samples as determined by microscopy increased again to 3.85 (Fig. 3b). Although frequently received blood transfusions (10 times comprised of 1 international unit of red cell suspension liquid and 100 ml of blood plasma, or 2 international unit of red cell suspension liquid and 200 ml of blood plasma each time), the patient became severely anemic. Her hospital course was complicated by refractory hypernatremia and hyperchloremia (sodium–153 mmol/L, chloride–114 mmol/L), leading to multiple blisters on the left leg (Fig. 1d). FLA-like pathogens were also detected in the blister fluid samples. She finally died of multiple organ failure and intractable fever on the 134th day of hospitalization.

Pathogen morphology

Prior to observing in the microscope, blood, CSF and blood samples were processed with the physiological saline method of direct smears.

In the blood samples, many cells looked like “straw hats” (Fig. 3a). The cells were discoid in shape; the cytoplasmic humps were surrounded with flattened hyaline margins, some of which were fan-shaped. The surfaces of the cells were warty. The dimensions of these cells ranged from 10.2–25.4 × 11.8–26.5 μm with average dimensions of 17.8 × 19.3 μm. Smaller cells were easily observed. Owing to the granular mass on the surface, the nucleus could be not clearly seen. Locomotion was not visible in most microscopic fields. But sometimes cells displayed short blunt or fila-pseudopodia and slow deformation (Additional file 4).

Additional file 4: Video. Short video clip of FLA-like pathogen in blood sample under microscopic vision. Locomotion was not visible in most microscopic fields. But sometimes cells displayed short blunt or fila-pseudopodia and slow deformation. (MP4 18 599 kb)

In CSF samples, we found different cells that appeared irregular and had vacuoles (Fig. 4a-c) and finger pseudopodia (Fig. 4c). Some had circular shells that looked transparent, but no structures could be observed (Fig. 4d). Occasionally, black spheres were observed (Fig. 4e).

In urine samples, single cells displayed different morphological forms; some were spherical (Fig. 4f-h, j, l, n), whereas others had huge vacuoles (Fig. 4k) and/or possessed fan-shaped pseudopodia (Fig. 4m). Some “cells” clustered together.

After the antiamebic treatment, when the body temperature of the patient came down, the discoid-like unicellular body could not be detected in blood samples (Fig. 3c g-n). Most forms were oval; the cell bodies were approximately 13.0–16.1 μm long and 8.8–11.7 μm wide with average dimensions of 15.0 × 10.1 μm. Locomotive cells displayed short filopodia or conical non-branching pseudopodia arising from apical and/or lateral parts of the cell (Fig. 3c k-n). Furthermore, some small cells showing small, refractive outlines with single long (over 10 μm) filopodia (Fig. 3c g, h) and large irregularly shaped cells (more than 10 μm) with short (3–5 μm) filopodia (Fig. 3c i, j) could be seen occasionally.

The morphological characteristics of the pathogen resemble species of FLA, Vannella sp. [27], and another type of scale-bearing amoeba: Cochliopodium sp. [28], and with no similarity with known pathogenic amoeba such as Acanthamoeba sp., Balamuthia mandrillaris, Entamoeba histolytica, Naegleria fowleri, Sappinia diploidea, etc. [29].

Molecular identification

To confirm the morphological findings and further discover the cause of the infection, uncultured blood serum samples were sent for molecular identification. The blood serum samples were taken on day 44 and preserved in liquid nitrogen. Total genomic DNA was extracted from the samples and polymerase chain reaction (PCR) was performed using prokaryotic universal primers and eukaryotic universal primers (Additional file 5). Primer sequences were 16 s-27F 5′-AGAGTTTGATCATGGCTCAG-3′, 16 s-1390R 5′-ACGGGCGGTGTCTACAA-3′, 18S-F 5′-ACCTGGTTGATCCTGCCAGT-3′, 18S-R 5′-CTTGTTACGACTTTTACTTCC-3′, 18S-1080F 5′-GGGRAACTTACCAGGTCC-3′ and 18S-1578R 5′-GTGATRWGRTTTACTTRT-3′. The obtained sequencing data (1300 bp) using prokaryotic primers were compared with all published sequences in GenBank using BLASTn at National Center for Biotechnology Information ( and submitted to the GenBank database (Accession No. MG581460). Results showed that the sequence had a maximum of 80% identities with multiple Acinetobacter baumannii strains (Additional file 6). Comparison of the obtained sequence with Acinetobacter baumannii strain KAB05, complete genome (Accession No. CP017650.1) was shown in Additional file 7. Another sequencing data (1800 bp) were obtained using eukaryotic universal primers pair 18S-F/18S-R and had a maximum of 99% identities with Human Genomic sequences. No sequencing data were obtained using universal primers pair 18S-1080F/18S-1578R.


We report a case of postoperative infection in a humeral head hemiarthroplasty patient caused by Acinetobacter baumannii, which was identified via molecular DNA sequencing. The pathogen was initially misidentified as a FLA species.

A. baumannii is recognized as an opportunist pathogen which causes infections in fragile patients [30, 31]. Infections caused by A. baumannii are usually associated with defects in anatomical host defenses and alteration of normal host flora by exposure to broad-spectrum antibiotics [32], affecting mainly severely ill patients in the ICUs, and patients who have trauma or suffer from burns [3, 32]. The most common mode of transmission is via the hands of health care workers [33, 34]. The most common clinical manifestations of A. baumannii are nosocomial pneumonia and bacteremia [16, 3540].

The exact time point of infection could not be established by now, but was speculated to be after the surgery. The route of infection in our patient is not clear. After scrutinizing the whole hospital course, we summarize the reasons for misdiagnosis and mistreatment into three points. First, clinical manifestations of this patient after infection were atypical. Common clinical manifestations of A. baumannii include nosocomial pneumonia, bacteremia, wound infections and osteomyelitis, urinary tract infections, endocarditis, and meningitis [16, 3540]. The patient only developed continuous fever. The operated upper limb healed uneventfully, and none of the common manifestations of A. baumannii above were developed. Second, blood culture was performed several times and revealed no bacterial growth. Two antibiotic agents used in FUO stage, namely, meropenem and cefoperazone/sulbactam, had antimicrobial activity against A. baumannii [41] and were among current treatment options to A. baumannii infections [32, 42, 43]. Negative results of blood culture may due to the use of meropenem and cefoperazone/sulbactam, along with other antimicrobial treatments. The last and most important, the pathogens observed microscopically were FLA-like, rather than A. baumannii. Its microscopic characteristics resemble Vannella sp. [27], and another type of scale-bearing amoeba: Cochliopodium sp. [28]. Diagnosis of FLA infection was mainly based on the microscopic findings. In addition, after the initiation of antiamebic therapy, a clinical remission was observed, making us further believe that the causative pathogen was a FLA species.

The sequences obtained using prokaryotic universal primers were compared with all published sequences in GenBank. According to the results from molecular DNA sequencing, the final diagnosis is A. baumannii infection. However, this alone cannot explain the discovery of many FLA-like pathogens microscopically.

Two hypotheses were established for this, though neither can be verified by now. One hypothesis is that the patient was infected with two pathogens, FLA and A. baumannii. The FLA could be a Vannella species based on its morphology and may serve as host for A. baumannii. Some of the Vannella species are known to harbor bacterial pathogens in previous studies [44, 45]. The empirical broad-spectrum antibiotic therapy destroyed most of the FLA later, leaving A. baumannii in the predominant position. Another hypothesis is the strange FLA-like pathogens were actually the blood cells or parts of them, which were invaded by A. baumannii and serve as hosts for them. Bacteria living within eukaryotic cells are called intracellular bacteria. Obligate intracellular bacteria enter into cells and use host cell resources for their replication [46], while facultative intracellular bacteria can multiply both inside and outside host cells [47]. Intracellular bacteria generally reside directly in the host cytoplasm or in host-derived vacuoles [48], some can even invade eukaryotic nucleus [49]. They frequently hijack the host endocytic and secretory pathway, and structure the host a specialized cell for their replication [50]. Many intracellular bacteria are well-known pathogens, including Legionella pneumophila [51], Francissella tularensis [52], and Mycobacterium tuberculosis [53]. A. baumannii is also facultative intracellular bacteria [54], and had been reported to adhere and invade into human pulmonary cells, causing respiratory infections and pneumonia [5557].

A. baumannii infections are commonly difficult to treat as the causative strains often have broad antimicrobial resistance. These A. baumannii strains are classified as multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR) based on their antimicrobial susceptibility profile. MDR strains are resistant to three or more, XDR strains are resistant to all but one or two, and PDR are resistant to all classes of potentially effective antimicrobial agents [58].

Current treatment options to A. baumannii infections include carbapenems, sulbactam, tigecycline, fluoroquinolones, aminoglycosides, colistin and rifampin [32, 42, 43]. Carbapenems have been regarded as the treatment of choice for severe A. baumannii infections [59, 60]. Strains respond briskly to carbapenems if they retain susceptibility to this antimicrobial class [15, 32]. However, increasing carbapenem-resistant A. baumannii strains are reported worldwide. Sulbactam is the most active of the β-lactamase inhibitors and has intrinsic antimicrobial activity against A. baumannii [41]. Sulbactam has shown promising results against A. baumannii strains with various susceptibility profiles [6164], but its antimicrobial activity has declined substantially recently [65, 66]. Another option to treat A. baumannii infections is tigecycline. Tigecycline is a broad-spectrum antibiotic with bacteriostatic activity against A. baumannii [67, 68] and is commonly reserved for salvage therapy [69]. If β-lactams cannot be used, fluoroquinolones and aminoglycosides can be considered as potential treatment options [32]. For XDR A. baumannii, polymyxins are often the last treatment option. Unfortunately, polymyxins suffer from high rates of nephrotoxicity and neurotoxicity and possess no therapeutic window [32]. Recent in vitro models suggest that rifampicin maintains a high level of activity against A. baumannii, even in carbapenem-resistant strains [42, 70]. However, rifampicin should not be used in monotherapy as it induces the resistance of A. baumannii to itself [42].

In the present case, although meropenem and cefoperazone/sulbactam, which were among treatment options to A. baumannii infections [32, 42, 43], were used in this case. However, these antibiotics were not used according to the treatment guidelines for A. baumannii and may not reach the minimum inhibitory concentration (MIC). In addition, the A. baumannii strains in this case report may be carbapenem-resistant, MDR, or even XDR, often leading to very high mortality.


This report presents a case of A. baumannii identified by molecular DNA sequencing, which was initially misidentified as a FLA species. Medical workers should be aware that patients associated with mechanical ventilation, surgery and invasive procedures, and prolonged broad-spectrum antimicrobials, especially those who suffer from burns, have trauma, or are in the ICUs, are among high risk-population of A. baumannii infection. If these patients develop FUO, A. baumannii infection should be taken into consideration. Clinically, due to the use of empirical antibiotics, blood culture results may be negative, and pathogen morphology under microscopic examination is sometimes atypical. In that case, the causative pathogen should be identified by molecular DNA sequencing if possible.



Antiamebic treatment


Compounded sulfamethoxazole and sulfadiazine


Cerebrospinal fluid


Free-living amoeba


Fever of unknown origin


Intensive care unit




Minimum inhibitory concentration


Polymerase chain reaction




Treatment failure


Extensively drug-resistant



The authors are grateful to the patient’s relative for full consent to the publication of this case report, and would like to thank the National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, for providing Duo-Cotecxin in the treatment of the patient.


This work was supported by grants from National Natural Science Foundation of China (31271015), and Key Basic Research Project of Science and Technology of Shanghai (13JC1403900).

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available since the medical records and data are the patient’s privacy, but are available from the corresponding author on reasonable request under the consent from close relatives of the patient.

Authors’ contributions

Jiaxin Tang performed the data, made the picture and wrote the manuscript. HZ and LC carried out the parasite detection and species identification. ZQ supervised the development of the manuscript. CY, ZQ, TT, Jian Tang, YS, ML and KD participated in the patient’s treatment. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent was obtained from the relative of the patient for publication of this Case Study and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China
Department of Microbiology and Parasitology, Second Military Medical University, Shanghai, 200433, China
Shanghai Municipal Center for Disease Control & Prevention, Shanghai, 200336, China
Medical 3D Printing Innovation Research Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200125, China
Engineering Research Center of Digital Medicine and Clinical Translation, Ministry of Education, Shanghai, 200030, China


  1. Daly AK, Postic B, Kass EH. Infections due to organisms of the genus Herellea. B5W and B anitratum. Arch Intern Med. 1962;110:580–91. ArticlePubMedGoogle Scholar
  2. Glew RH, Moellering RC Jr, Kunz LJ. Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies. Medicine (Baltimore). 1977;56:79–97.View ArticleGoogle Scholar
  3. Falagas M, Bliziotis I, Siempos I. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care. 2006;10(2):R48.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Bouvet JM, Grimont PAD. Taxonomy of the genus Acinetobacter with the recognition of Acinetobacter baumannii sp. nov. Acinetobacter haemolyticus sp. nov. Acinetobacter johnsonii sp. nov. and Acinetobacter junii sp. nov. and emended descriptions of Acinetobacter calcoaceticus and Acinetobacter lwofii. Int J Syst Bacteriol. 1986;68:228–40.View ArticleGoogle Scholar
  5. Baumann P, Doudoroff M, Stanier RY. A study of the Moraxella group. II. Oxidative-negative species (genus Acinetobacter). J Bacteriol. 1968;95(5):1520–41.PubMedPubMed CentralGoogle Scholar
  6. Cerqueira GM, Peleg AY. Insights into Acinetobacter baumannii pathogenicity. IUBMB Life. 2011;63(12):1055–60.View ArticlePubMedGoogle Scholar
  7. Tognim MC, Andrade SS, Silbert S, Gales AC, Jones RN, Sader HS. Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY antimicrobial surveillance program. Int J Infect Dis. 2004;8(5):284–91.View ArticlePubMedGoogle Scholar
  8. van Dessel H, Dijkshoorn L, van der Reijden T, Bakker N, Paauw A, van den Broek P, Verhoef J, Brisse S. Identification of a new geographically widespread multiresistant Acinetobacter baumannii clone from European hospitals. Res Microbiol. 2004;155(2):105–12.View ArticlePubMedGoogle Scholar
  9. Anstey NM, Currie BJ, Hassell M, Palmer D, Dwyer B, Seifert H. Community-acquired bacteremic Acinetobacter pneumonia in tropical Australia is caused by diverse strains of Acinetobacter baumannii, with carriage in the throat in at-risk groups. J Clin Microbiol. 2002;40(2):685–6.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Gaynes R, Edwards JR. National Nosocomial Infections Surveillance S. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41(6):848–54.View ArticlePubMedGoogle Scholar
  11. Kanafani ZA, Kara L, Hayek S, Kanj SS. Ventilator-associated pneumonia at a tertiary-care center in a developing country: incidence, microbiology, and susceptibility patterns of isolated microorganisms. Infect Control Hosp Epidemiol. 2003;24(11):864–9.View ArticlePubMedGoogle Scholar
  12. Paul M, Weinberger M, Siegman-Igra Y, Lazarovitch T, Ostfeld I, Boldur I, Samra Z, Shula H, Carmeli Y, Rubinovitch B, et al. Acinetobacter baumannii: emergence and spread in Israeli hospitals 1997-2002. J Hosp Infect. 2005;60(3):256–60.View ArticlePubMedGoogle Scholar
  13. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39(3):309–17.View ArticlePubMedGoogle Scholar
  14. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538–82.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46(8):1254–63.View ArticlePubMedGoogle Scholar
  16. Joly-Guillou ML. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect. 2005;11:868–73.View ArticlePubMedGoogle Scholar
  17. Chung DR, Song JH, Kim SH, Thamlikitkul V, Huang SG, Wang H, So TM, Yasin RM, Hsueh PR, Carlos CC, et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med. 2011;184(12):1409–17.View ArticlePubMedGoogle Scholar
  18. Freire MP, de Oliveira GD, Garcia CP, Campagnari Bueno MF, Camargo CH, Kono Magri ASG, Francisco GR, Reghini R, Vieira MF, Ibrahim KY, et al. Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia. Clin Microbiol Infect. 2016;22(4):352–8.View ArticlePubMedGoogle Scholar
  19. Chopra T, Marchaim D, Johnson PC, Awali RA, Doshi H, Chalana I, Davis N, Zhao JJ, Pogue JM, Parmar S, et al. Risk factors and outcomes for patients with bloodstream infection due to Acinetobacter baumannii-calcoaceticus complex. Antimicrob Agents Chemother. 2014;58(8):4630–5.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Chopra T, Marchaim D, Awali RA, Krishna A, Johnson P, Tansek R, Chaudary K, Lephart P, Slim J, Hothi J, et al. Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes. Antimicrob Agents Chemother. 2013;57(12):6270–5.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Neer CS 2nd. Displaced proximal humeral fractures. I. Classification and evaluation. J Bone Joint Surg Am. 1970;52(6):1077–89.View ArticlePubMedGoogle Scholar
  22. Deng Y, Ran W, Man S, Li X, Gao H, Tang W, Tachibana H, Cheng X. Artemether exhibits Amoebicidal activity against Acanthamoeba castellanii through inhibition of the serine biosynthesis pathway. Antimicrob Agents Chemother. 2015;59(8):4680–8.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Maritschnegg P, Sovinz P, Lackner H, Benesch M, Nebl A, Schwinger W, Walochnik J, Urban C. Granulomatous amebic encephalitis in a child with acute lymphoblastic leukemia successfully treated with multimodal antimicrobial therapy and hyperbaric oxygen. J Clin Microbiol. 2011;49(1):446–8.View ArticlePubMedGoogle Scholar
  24. Petry F, Torzewski M, Bohl J, Wilhelm-Schwenkmezger T, Scheid P, Walochnik J, Michel R, Zoller L, Werhahn KJ, Bhakdi S, et al. Early diagnosis of Acanthamoeba infection during routine cytological examination of cerebrospinal fluid. J Clin Microbiol. 2006;44(5):1903–4.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Ranjan R, Handa A, Choudhary A, Kumar S. Acanthamoeba infection in an interhemispheric ependymal cyst: a case report. Surg Neurol. 2009;72(2):185–9.View ArticlePubMedGoogle Scholar
  26. Singhal T, Bajpai A, Kalra V, Kabra SK, Samantaray JC, Satpathy G, Gupta AK. Successful treatment of Acanthamoeba meningitis with combination oral antimicrobials. Pediatr Infect Dis J. 2001;20:623–7.View ArticlePubMedGoogle Scholar
  27. Protist Information Server. The graduate University for Advanced Studies, and Japan Science and Technology Corporation, Japan. 2002. Accessed 19 Sept 2017.Google Scholar
  28. Professionelle Dokumentation. Gerd Günther. 2016. Accessed 19 Sept 2017.Google Scholar
  29. John JL, Gordon FL, Phyllis B. An illustrated guide to the protozoa. 2nd ed. Lawrence, Kansas: Society of Protozoologists, Allen Press, Inc; 2000.Google Scholar
  30. Shelburne SA 3rd, Singh KV, White AC Jr, Byrne L, Carmer A, Austin C, Graviss E, Stager C, Murray BE, Atmar RL. Sequential outbreaks of infections by distinct Acinetobacter baumannii strains in a public teaching hospital in Houston, Texas. J Clin Microbiol. 2008;46(1):198–205.View ArticlePubMedGoogle Scholar
  31. Garcia-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jimenez-Jimenez FJ, Monterrubio-Villar J, Gili-Miner M. Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients. Crit Care Med. 1999;27(9):1794–9.View ArticlePubMedGoogle Scholar
  32. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and pathophysiological overview of Acinetobacter Infections: a century of challenges. Clin Microbiol Rev. 2017;30(1):409–47.PubMedGoogle Scholar
  33. McDonald LC, Banerjee SN, Jarvis WR. Seasonal variation of Acinetobacter infections: 1987-1996. Nosocomial infections surveillance system. Clin Infect Dis. 1999;29(5):1133–7.View ArticlePubMedGoogle Scholar
  34. Spellberg B, Bonomo RA. “Airborne assault”: a new dimension in Acinetobacter baumannii transmission. Crit Care Med. 2013;41(8):2042–4. ArticlePubMedGoogle Scholar
  35. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S, National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34:1–14.View ArticlePubMedGoogle Scholar
  36. Raad II, Mohamed JA, Reitzel RA, Jiang Y, Dvorak TL, Ghannoum MA, Hachem RY, Chaftari AM. The prevention of biofilm colonization by multidrug-resistant pathogens that cause ventilator-associated pneumonia with antimicrobial-coated endotracheal tubes. Biomaterials. 2011;32(11):2689–94.View ArticlePubMedGoogle Scholar
  37. Gil-Perotin S, Ramirez P, Marti V, Sahuquillo JM, Gonzalez E, Calleja I, Menendez R, Bonastre J. Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of concept. Crit Care. 2012;16(3):R93.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Davis KA, Moran KA, McAllister CK, Gray PJ. Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis. 2005;11(8):1218–24. ArticlePubMedPubMed CentralGoogle Scholar
  39. Yun HC, Branstetter JG, Murray CK. Osteomyelitis in military personnel wounded in Iraq and Afghanistan. J Trauma. 2008;64(2 Suppl):S163–8. discussion S168View ArticlePubMedGoogle Scholar
  40. de Carvalho VC, de Oliveira PRD, Dal-Paz K, de Paula AP, CdS F, ALL ML. Gram-negative osteomyelitis: clinical and microbiological profile. Braz J Infect Dis. 2012;16(1):63–7.Google Scholar
  41. Rafailidis PI, Ioannidou EN, Falagas ME. Ampicillin/sulbactam: current status in severe bacterial infections. Drugs. 2007;67(13):1829–49.View ArticlePubMedGoogle Scholar
  42. Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis. 2010;23(4):332–9.View ArticlePubMedGoogle Scholar
  43. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis. 2008;8(12):751–62.View ArticlePubMedGoogle Scholar
  44. Hoffmann R, Michel R, Schmid EN, Muller KD. Natural infection with microsporidian organisms (KW19) in Vannella spp. (Gymnamoebia) isolated from a domestic tap-water supply. Parasitol Res. 1998;84(2):164–6.View ArticlePubMedGoogle Scholar
  45. Michel R, Schmid EN, Boker T, Hager DG, Muller KD, Hoffmann R, Seitz HM. Vannella sp. harboring microsporidia-like organisms isolated from the contact lens and inflamed eye of a female keratitis patient. Parasitol Res. 2000;86(6):514–20.View ArticlePubMedGoogle Scholar
  46. Silva MT. Classical labeling of bacterial pathogens according to their lifestyle in the host: inconsistencies and alternatives. Front Microbiol. 2012;3:71. ArticlePubMedPubMed CentralGoogle Scholar
  47. Ribet D, Cossart P. How bacterial pathogens colonize their hosts and invade deeper tissues. Microbes Infect. 2015;17(3):173–83.View ArticlePubMedGoogle Scholar
  48. Ray K, Marteyn B, Sansonetti PJ, Tang CM. Life on the inside: the intracellular lifestyle of cytosolic bacteria. Nat Rev Microbiol. 2009;7(5):333–40.View ArticlePubMedGoogle Scholar
  49. Schulz F, Horn M. Intranuclear bacteria: inside the cellular control center of eukaryotes. Trends Cell Biol. 2015;25(6):339–46.View ArticlePubMedGoogle Scholar
  50. Canton J, Kima PE. Interactions of pathogen-containing compartments with the secretory pathway. Cell Microbiol. 2012;14(11):1676–86.View ArticlePubMedGoogle Scholar
  51. Swanson MS, Hammer BK. Legionella pneumophila pathogesesis: a fateful journey from amoebae to macrophages. Annu Rev Microbiol. 2000;54:567–613.View ArticlePubMedGoogle Scholar
  52. Abd H, Johansson T, Golovliov I, Sandstrom G, Forsman M. Survival and growth of Francisella tularensis in Acanthamoeba castellanii. Appl Environ Microbiol. 2003;69(1):600–6.View ArticlePubMedPubMed CentralGoogle Scholar
  53. Mba Medie F, Ben Salah I, Henrissat B, Raoult D, Drancourt M. Mycobacterium tuberculosis complex mycobacteria as amoeba-resistant organisms. PLoS One. 2011;6(6):e20499.View ArticlePubMedPubMed CentralGoogle Scholar
  54. Niller HH, Masa R, Venkei A, Meszaros S, Minarovits J. Pathogenic mechanisms of intracellular bacteria. Curr Opin Infect Dis. 2017;30(3):309–15.View ArticlePubMedGoogle Scholar
  55. Lee JC, Oh JY, Kim KS, Jeong YW, Park JC, Cho JW. Apoptotic cell death induced by Acinetobacter baumannii in epithelial cells through caspase-3 activation. APMIS. 2001;109(10):679–84.View ArticlePubMedGoogle Scholar
  56. Lee JC, Koerten H, van den Broek P, Beekhuizen H, Wolterbeek R, van den Barselaar M, van der Reijden T, van der Meer J, van de Gevel J, Dijkshoorn L. Adherence of Acinetobacter baumannii strains to human bronchial epithelial cells. Res Microbiol. 2006;157(4):360–6.View ArticlePubMedGoogle Scholar
  57. Choi CH, Lee JS, Lee YC, Park TI, Lee JC. Acinetobacter baumannii invades epithelial cells and outer membrane protein a mediates interactions with epithelial cells. BMC Microbiol. 2008;8:216.View ArticlePubMedPubMed CentralGoogle Scholar
  58. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81.View ArticlePubMedGoogle Scholar
  59. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996;9(2):148–65.PubMedPubMed CentralGoogle Scholar
  60. Van Looveren M, Goossens H. ARPAC steering group. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect. 2004;10(8):684–704.View ArticlePubMedGoogle Scholar
  61. Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect Dis. 2006;6:130.View ArticlePubMedPubMed CentralGoogle Scholar
  62. Marchaim D, Navon-Venezia S, Leavitt A, Chmelnitsky I, Schwaber MJ, Carmeli Y. Molecular and epidemiologic study of polyclonal outbreaks of multidrug-resistant Acinetobacter baumannii infection in an Israeli hospital. Infect Control Hosp Epidemiol. 2007;28(8):945–50.View ArticlePubMedGoogle Scholar
  63. Marques MB, Waites KB, Mangino JE, Hines BB, Moser SA. Genotypic investigation of multidrug-resistant Acinetobacter baumannii infections in a medical intensive care unit. J Hosp Infect. 1997;37(2):125–35.View ArticlePubMedGoogle Scholar
  64. Ayats J, Corbella X, Ardanuy C, Dominguez MA, Ricart A, Ariza J, Martin R, Linares J. Epidemiological significance of cutaneous, pharyngeal, and digestive tract colonization by multiresistant Acinetobacter baumannii in ICU patients. J Hosp Infect. 1997;37(4):287–95.View ArticlePubMedGoogle Scholar
  65. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect. 2006;12(4):315–21.View ArticlePubMedGoogle Scholar
  66. Insa R, Cercenado E, Goyanes MJ, Morente A, Bouza E. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J Antimicrob Chemother. 2007;59(3):583–5.View ArticlePubMedGoogle Scholar
  67. Seifert H, Stefanik D, Wisplinghoff H. Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J Antimicrob Chemother. 2006;58(5):1099–100.View ArticlePubMedGoogle Scholar
  68. Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C, Llanos AC, Pachon J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother. 2004;48(11):4479–81.View ArticlePubMedPubMed CentralGoogle Scholar
  69. Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, Capitano B, Husain S, Kwak EJ, Bhat SV, Paterson DL. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother. 2007;59(1):128–31.View ArticlePubMedGoogle Scholar
  70. Lopez-Rojas R, Dominguez-Herrera J, McConnell MJ, Docobo-Perez F, Smani Y, Fernandez-Reyes M, Rivas L, Pachon J. Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. J Infect Dis. 2011;203(4):545–8.View ArticlePubMedPubMed CentralGoogle Scholar


© The Author(s). 2018